Journal of Psychiatric Research
June 12, 2026
Juliana Lima Constantino, Tobias Stephan Freimann, Jens H van Dalfsen et al.
Oral esketamine is a potentially effective and well-tolerated treatment for treatment-resistant depression (TRD). However, around 50% of TRD individuals treated with oral esketamine do not achieve response, and this variation in response may be accounted for by interindividual differences between patients. Efforts to develop effective and personalized depression treatment strategies are...
Journal of Surgery and Medicine
June 11, 2026
Davon Lee, Elizabeth Beyene, Da’Jhai Monroe et al.
Background/Aim: Ketamine is frequently administered for analgesia and sedation during burn dressing changes, but its potential psychological impact remains a concern. This study assessed whether ketamine exposure during early burn care is associated with subsequent depression, acute stress reaction (ASR), or post-traumatic stress disorder (PTSD) in patients with major burns. Methods: A...
Australasian Psychiatry
June 11, 2026
Eden Mane, Saras Mane
ObjectivesTo systematically review the effectiveness, safety, and care models of telehealth-supported ketamine for depression and/or anxiety in adults and consider implications for Australasian clinical practice.MethodsFollowing PRISMA 2020, we searched for randomised or observational studies of adults receiving at-home telehealth-supported ketamine for depression and/or anxiety, to August...
European Psychiatry
June 10, 2026
Riccardo Guglielmo, Miriam Olivola, Alberto Inuggi et al.
Esketamine has demonstrated efficacy in treatment-resistant depression (TRD), but medium-term real-world functional outcomes remain understudied. This study described 6-month depressive symptoms and functional trajectories during routine esketamine treatment, focusing on functional outcomes and remission correlates. In this prospective multicenter study, 60 patients with TRD initiating...
Journal of Psychoactive Drugs
June 10, 2026
Jack H Buchanan, Brandon Reynante, Michael T. Dinh et al.
Ketamine-assisted psychotherapy (KAP) is an emerging treatment approach that may enhance ketamine's antidepressant effects through neuroplastic synergism or transformative psychological experience. Despite growing clinical use, real-world KAP practices remain understudied. This cross-sectional survey examined the practices of fifty licensed KAP providers treating depression, recruited from a...
Fortschritte der Neurologie · Psychiatrie
June 8, 2026
Udo Bonnet, Norbert Scherbaum, Georg Juckel et al.
Introduction: Esketamine nasal spray (EN) has been approved in Germany since 2021 for the treatment of treatment-resistant depression (TRD). Historically, the development of EN resulted from the positive results of randomized clinical trials on the off-label use of subnarcotic ketamine infusions (SKI) for TRD. How effective, tolerable, and safe is off-label SKI compared to EN? Methods: Narrativ...
Journal of Affective Disorders
June 8, 2026
Dian‐jeng Li, Tien-Wei Hsu, Te-Chang Changchien et al.
Little is known about esketamine's effectiveness for patients with major depressive disorder (MDD) comorbid substance use disorders (SUD). We conducted a retrospective cohort study using the TriNetX US Collaborative Network, including adults aged ≥18 years with MDD. Three propensity-score-matched (1:1) cohorts were defined based on treatment: esketamine, antidepressant-only, and repetitive...
Journal of Affective Disorders
June 7, 2026
Lindsay L Benster, Jordan N Kohn, Benjamin Wade et al.
Repetitive transcranial magnetic stimulation (rTMS) and intranasal esketamine are FDA-approved for treatment-resistant depression (TRD), yet comparative real-world data on response trajectories and predictors of outcomes remain limited. A retrospective analysis was performed using electronic medical records from UC San Diego Health. Adults with TRD treated with rTMS (n = 279) or intranasal...
Psychopharmacology Bulletin
June 5, 2026
Keming Gao, Evrim Bayrak Oruc, Heather Wobbe et al.
To compare the efficacy and safety of electroconvulsive therapy (ECT) and ketamine infusion (KET-IFU) in routine care for patients with bipolar I or II depression (BPD). Electronic medical records of patients who received ECT and/or KET-IFU were used to identify patients with BPD who received both ECT and KET-IFU treatments. The change in the 16-item Quick Inventory of Depressive Symptomatology...
European Psychiatry
June 1, 2026
P.-M. Llorca, Ludovic Samalin, Emilie Olié et al.
Introduction: Esketamine nasal spray (ESK) was approved in 2019 in Europe for adults with Treatment-Resistant Depression (TRD), defined as inadequate response to at least two different antidepressants during the current moderate to severe depressive episode Objectives: To assess patient-reported outcomes related to symptomatology, quality of life, and occupational impairment over 12 months...